Login to Your Account

Withdrawn antibody, CAR T and two biosimilars in ODAC lineup

By Mari Serebrov
Regulatory Editor

Monday, July 10, 2017

The FDA’s ODAC will have a lot to consider this week in three days of back-to-back meetings in which it will be asked to weigh in on four different biologic candidates.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription